Merus Labs International Inc. (TSE:MSL – Free Report) (NASDAQ:MSLI) – Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for Merus Labs International in a research report issued to clients and investors on Friday, August 22nd. HC Wainwright analyst A. He forecasts that the specialty pharmaceutical company will post earnings per share of ($0.06) for the quarter. HC Wainwright also issued estimates for Merus Labs International’s Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.06) EPS and Q4 2026 earnings at ($0.06) EPS.
Merus Labs International Price Performance
Merus Labs International has a 52 week low of C$0.95 and a 52 week high of C$1.76.
About Merus Labs International
Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.
Featured Stories
- Five stocks we like better than Merus Labs International
- How to Read Stock Charts for Beginners
- As Trump Blocks Clean Energy, What’s Next for Renewables?
- 3 REITs to Buy and Hold for the Long Term
- How a Superstore Strategy Fueled MINISO’s 20% Stock Surge
- Asset Allocation Strategies in Volatile Markets
- Analysts Love These 3 Companies Reporting Earnings This Week
Receive News & Ratings for Merus Labs International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International and related companies with MarketBeat.com's FREE daily email newsletter.
